June 22, 2026 Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
June 22, 2026 GrowGeneration to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23, 2026
June 22, 2026 BiggerPockets Appoints Active Real Estate Investor Eric Augustyn as CEO, Ushering in a New Era of Platform Innovation
June 22, 2026 Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis
